Checkpoint inhibitor therapy targeted at immune cells associated with checkpoint proteins, like PD-L1, PD-L2, B7-H3, and CTLA-4, could help disinhibit the host immune system to help combat tumor survival and growth (43, 80, 92, 94). The gene discussed is CTLA4; the disease is neoplasm.